SA521421997B1 - مركب 1، 3، 4-أكسا ديازولون ومستحضر صيدلاني - Google Patents

مركب 1، 3، 4-أكسا ديازولون ومستحضر صيدلاني

Info

Publication number
SA521421997B1
SA521421997B1 SA521421997A SA521421997A SA521421997B1 SA 521421997 B1 SA521421997 B1 SA 521421997B1 SA 521421997 A SA521421997 A SA 521421997A SA 521421997 A SA521421997 A SA 521421997A SA 521421997 B1 SA521421997 B1 SA 521421997B1
Authority
SA
Saudi Arabia
Prior art keywords
compounds
inhibitory activity
present
pharmaceutical preparation
compound
Prior art date
Application number
SA521421997A
Other languages
English (en)
Inventor
كيكوتشي تاكيو
هاروتا يوشيناري
كاميتاني هيروتاكا
زايموكو هيساكي
Original Assignee
نيبون شينياكو كو.، ليمتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by نيبون شينياكو كو.، ليمتد filed Critical نيبون شينياكو كو.، ليمتد
Publication of SA521421997B1 publication Critical patent/SA521421997B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

يتعلق الاختراع الحالي بمركب له نشاط مثبط لـ PIM. تتضمن أمثلة للاختراع مركبات 1، 3، 4-أكسا ديازولون التي لها الصيغة التالية [1]، وأملاح وذوابات مقبولة صيدلانيًا منها. [المركب الكيميائي 1] تتميز مركبات الاختراع الحالي بأن لها نشاط مثبط لـ PIM. بالإضافة إلى ذلك، نظرا لأن مركبات الاختراع الحالي لها نشاط مثبط لـ PIM، فإنها مفيدة كعوامل علاجية للذئبة الحمامية الجهازية والتهاب الكلية الذئبي ، وما إلى ذلك.
SA521421997A 2018-11-15 2021-05-10 مركب 1، 3، 4-أكسا ديازولون ومستحضر صيدلاني SA521421997B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018214950 2018-11-15

Publications (1)

Publication Number Publication Date
SA521421997B1 true SA521421997B1 (ar) 2025-04-10

Family

ID=70731909

Family Applications (1)

Application Number Title Priority Date Filing Date
SA521421997A SA521421997B1 (ar) 2018-11-15 2021-05-10 مركب 1، 3، 4-أكسا ديازولون ومستحضر صيدلاني

Country Status (22)

Country Link
US (1) US20220024921A1 (ar)
EP (1) EP3882239A4 (ar)
JP (1) JP7434172B2 (ar)
KR (1) KR20210091767A (ar)
CN (1) CN113302184B (ar)
AU (1) AU2019381493B2 (ar)
BR (1) BR112021009198A2 (ar)
CA (1) CA3117550A1 (ar)
CL (1) CL2021001275A1 (ar)
CO (1) CO2021007442A2 (ar)
EA (1) EA202191349A1 (ar)
EC (1) ECSP21034281A (ar)
IL (1) IL282999A (ar)
MA (1) MA54243A (ar)
MX (1) MX2021005566A (ar)
PE (1) PE20211283A1 (ar)
PH (1) PH12021551103A1 (ar)
SA (1) SA521421997B1 (ar)
SG (1) SG11202104371XA (ar)
TW (1) TWI840448B (ar)
UA (1) UA129949C2 (ar)
WO (1) WO2020100959A1 (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023210599A1 (ar) 2022-04-25 2023-11-02
CN117285459B (zh) * 2023-11-24 2024-02-27 上海美迪西生物医药股份有限公司 一种小分子激酶抑制剂化合物的制备方法
CN118515653B (zh) * 2024-07-23 2024-12-10 西湖制药(杭州)有限公司 一种ezh2特异性抑制剂及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01139581A (ja) * 1987-08-20 1989-06-01 Nissan Chem Ind Ltd テトラヒドロフタルイミド誘導体、その製法および除草剤
TW200526626A (en) * 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
US20090105221A1 (en) 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
JP2008525486A (ja) 2004-12-22 2008-07-17 メルク エンド カムパニー インコーポレーテッド 置換ピペリジンの製造方法
AU2009219154A1 (en) * 2008-02-29 2009-09-03 Cylene Pharmaceuticals, Inc. Protein kinase modulators
GB0813740D0 (en) 2008-07-28 2008-09-03 Angeletti P Ist Richerche Biologica Therapeutic compounds
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
MX2013006467A (es) 2010-12-09 2013-10-01 Amgen Inc Compuestos biciclicos como inhibidores pim.
EP2688886A1 (en) 2011-03-22 2014-01-29 Amgen Inc. Azole compounds as pim inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
WO2013182546A1 (en) 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase
GB201814151D0 (en) 2018-08-31 2018-10-17 Ucl Business Plc Compounds

Also Published As

Publication number Publication date
CL2021001275A1 (es) 2021-11-05
CO2021007442A2 (es) 2021-06-21
CN113302184A (zh) 2021-08-24
TW202031649A (zh) 2020-09-01
AU2019381493B2 (en) 2024-10-31
SG11202104371XA (en) 2021-05-28
ECSP21034281A (es) 2021-06-30
PE20211283A1 (es) 2021-07-19
MA54243A (fr) 2021-09-22
EP3882239A1 (en) 2021-09-22
CA3117550A1 (en) 2020-05-22
MX2021005566A (es) 2021-07-15
EP3882239A4 (en) 2022-08-10
TWI840448B (zh) 2024-05-01
US20220024921A1 (en) 2022-01-27
UA129949C2 (uk) 2025-09-24
WO2020100959A1 (ja) 2020-05-22
KR20210091767A (ko) 2021-07-22
PH12021551103A1 (en) 2021-11-22
CN113302184B (zh) 2024-11-22
BR112021009198A2 (pt) 2021-08-03
JPWO2020100959A1 (ja) 2021-10-07
AU2019381493A1 (en) 2021-06-03
EA202191349A1 (ru) 2021-08-10
JP7434172B2 (ja) 2024-02-20
IL282999A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
MX391812B (es) Agonista fxr derivado de esteroides.
MX384868B (es) Composiciones para tratar atrofia muscular espinal.
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
MX383856B (es) Compuestos y composiciones para inhibir la actividad de shp2.
EP4609866A3 (en) Oxysterols and methods of use thereof
MX380928B (es) Inhibidores de kras g12c.
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
MX389142B (es) Compuestos espiro triciclicos.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
EP4316591A3 (en) Oxysterols and methods of use thereof
SA521421997B1 (ar) مركب 1، 3، 4-أكسا ديازولون ومستحضر صيدلاني
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
BR112013017302A2 (pt) formulações de imunossupressor
SA520411787B1 (ar) مشتقات بنزيميدازول واستخداماتها
EA201890532A1 (ru) Новые аннелированные бензамиды
BR112021011325A2 (pt) Derivados de rapamicina
MY197561A (en) Composition for increasing expression of pgc-1?
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
PH12020551342A1 (en) Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof